Pfizer Inc. (ETR:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 126.45B +8.9% |
| Revenue (ttm) | 54.96B +1.4% |
| Net Income | 6.50B -5.0% |
| EPS | 1.14 -5.1% |
| Shares Out | n/a |
| PE Ratio | 19.45 |
| Forward PE | 8.87 |
| Dividend | 1.47 (6.53%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | 3,847 |
| Open | 22.26 |
| Previous Close | 22.52 |
| Day's Range | 22.23 - 22.27 |
| 52-Week Range | 20.00 - 24.92 |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Consistent financial outperformance and strategic transformation have positioned the business for growth beyond COVID, with a diversified pipeline in oncology, obesity, and immunology. AI and China are seen as key industry disruptors, while upcoming product launches and strong M&A execution support a high single-digit revenue CAGR from 2029.
Pfizer says FDA approves expanded indication for Hympavzi
Pfizer (PFE) announced that the U.S. FDA has approved an expanded indication for Hympavzi to include the treatment of patients with hemophilia A or B 12 years and older with…
US FDA approves Pfizer's bleeding disorder drug for children
The U.S. Food and Drug Administration has approved Pfizer's drug to prevent or reduce the frequency of bleeding episodes in children and in certain patients with hemophilia, the company said on Mond...
U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HYMPAVZI® (marstacimab-hncq) to include the ...
Pfizer presents results from Phase 2b studies of berobenatide
Pfizer (PFE) presented detailed results from multiple Phase 2b studies of berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide, during a late-breaking expe...
Pfizer Transcript: Study update
Phase IIb data show monthly berobenatide delivers weight loss comparable to weekly tirzepatide and superior to semaglutide, with favorable GI tolerability and no discontinuations due to adverse events. Ten phase III trials are advancing, targeting broad obesity and comorbidity indications.
Pfizer Slides: Study update
Pfizer has posted slides in relation to its latest quarterly earnings report, which was published on June 6, 2026.
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Pfizer presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through its purchase of Metsera last year had a similar side-effect profile as rival Novo Nor...
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF'3944), an investigational, potential first-in-class monthly GLP-1...
Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the company engineering AI models to discover new molecules, announces a license agreement with Pfizer.
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it's in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes h...
Pfizer Transcript: Jefferies Global Healthcare Conference 2026
The CEO outlined a strategic shift toward oncology, leveraging recent acquisitions and global partnerships, especially in China, to drive innovation. AI and organizational transformation are central to future competitiveness, while regulatory and geopolitical dynamics shape industry priorities.
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Gold...
Pfizer announces results from Cohort 3 on Bratovi with cetuximab, Folfiri
Pfizer (PFE) announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 Breakwater trial, evaluating Bratovi in combination with cetuximab and F...
Pfizer announces results from Phase 3 Talapro-3 study of Talzenna, Xtandi
Pfizer (PFE) announced detailed results from the Phase 3 Talapro-3 study of Talzenna, an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi, an androgen receptor pathway inhibitor, ...
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating...
Mailbag: A Follow-Up on Pfizer & Other Questions
Two weeks ago, I said that one of my favorite stocks right now is Pfizer (PFE). The pharmaceutical giant is in the middle of a transformational period with the goal to return to growth by 2029.
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
NEW YORK--(BUSINESS WIRE)--TALAPRO-3 Data Presented at ASCO.
Pfizer announces seven-year follow-up results from Phase 3 CROWN trial
Pfizer (PFE) announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating Lorbrena versus Xalkori in people with previously untreated, anaplastic lymphoma kinase-positi...
Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhi...
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates. Innovent will will co-commercialize with Pfizer in th...
China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal
Chinese biopharmaceutical firm Innovent Biologics and U.S. pharma giant Pfizer have struck a global licensing and collaboration deal worth up to $10.5 billion to research and develop 12 ear...
Pfizer enters into global strategic collaboration with Innovent Biologics
Pfizer (PFE) and Innovent Biologics (IVBXF) announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new brea...
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic...
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
NEW YORK & SAN FRANCISCO & SUZHOU, China--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing...